治疗偏头痛的降钙素基因相关肽受体拮抗药:zavegepant  

A new drug of calcitonin gene-related peptide receptor antagonists for the treatment of migraine:zavegepant

作　　者：张文竹[1] 石杰[1] 宋旭霞[2] ZHANG Wen-zhu;SHI Jie;SONG Xu-xia(Department of Drug Clinical Trials/National Medical Products Administration Key Laboratory for Quality Research and Evaluation of Traditional Marine Chinese Medicine,Qingdao 266011,Shandong Province,China;Department of Neurology,Qingdao Hospital,University of Health and Rehabilitation Sciences(Qingdao Municipal Hospital),Qingdao 266011,Shandong Province,China)

机构地区：[1]康复大学青岛医院(青岛市市立医院)药物临床试验研究科/国家药品监督管理局海洋中药质量研究与评价重点实验室,山东青岛266011 [2]康复大学青岛医院(青岛市市立医院)神经内科,山东青岛266011

出　　处：《中国临床药理学杂志》2023年第16期2414-2417,共4页The Chinese Journal of Clinical Pharmacology

摘　　要：Zavegepant是2023年3月由美国食品药品监督管理局批准的首个降钙素基因相关肽(CGRP)受体拮抗药鼻腔喷雾剂,用于成人有先兆或无先兆偏头痛的急性治疗。Zavegepant是一种高选择性的CGRP受体拮抗药,最常见的药物不良反应主要为味觉障碍、恶心、鼻腔不适和呕吐。本文对zavegepant的作用机制、药代动力学、临床研究及安全性等方面进行介绍。Objective Zavegepant was the first nasal spray of calcitonin gene-related peptide(CGRP)receptor antagonist approved by the US Food and Drug Administration(FDA)in March 2023 for the acute treatment of migraine with or without aura in adults.Zavegepant is a highly selective CGRP receptor antagonist.The most common adverse reactions were taste disorders,nausea,nasal discomfort and vomiting.This article introduced the mechanism of action,pharmacokinetics,clinical researches and safety of zavegepant.

关 键 词：zavegepant 降钙素基因相关肽受体拮抗药 偏头痛 

分 类 号：R97[医药卫生—药品]